These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30900137)

  • 41. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
    Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
    Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant treatments for triple-negative breast cancers.
    Joensuu H; Gligorov J
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi40-5. PubMed ID: 23012301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
    Fountzilas G; Dafni U; Dimopoulos MA; Koutras A; Skarlos D; Papakostas P; Gogas H; Bafaloukos D; Kalogera-Fountzila A; Samantas E; Briasoulis E; Pectasides D; Maniadakis N; Matsiakou F; Aravantinos G; Papadimitriou C; Karina M; Christodoulou C; Kosmidis P; Kalofonos HP
    Breast Cancer Res Treat; 2009 May; 115(1):87-99. PubMed ID: 18483853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
    Mauri D; Polyzos NP; Salanti G; Pavlidis N; Ioannidis JP
    J Natl Cancer Inst; 2008 Dec; 100(24):1780-91. PubMed ID: 19066278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
    Ellis P; Barrett-Lee P; Johnson L; Cameron D; Wardley A; O'Reilly S; Verrill M; Smith I; Yarnold J; Coleman R; Earl H; Canney P; Twelves C; Poole C; Bloomfield D; Hopwood P; Johnston S; Dowsett M; Bartlett JM; Ellis I; Peckitt C; Hall E; Bliss JM; ;
    Lancet; 2009 May; 373(9676):1681-92. PubMed ID: 19447249
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
    Brandi M; Vici P; Lopez M; Valerio MR; Giotta F; Gebbia N; Schittulli F; Colucci G;
    Semin Oncol; 2004 Apr; 31(2 Suppl 5):13-9. PubMed ID: 15199527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Fumoleau P; Largillier R; Clippe C; Dièras V; Orfeuvre H; Lesimple T; Culine S; Audhuy B; Serin D; Curé H; Vuillemin E; Morère JF; Montestruc F; Mouri Z; Namer M
    Eur J Cancer; 2004 Mar; 40(4):536-42. PubMed ID: 14962720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
    Thomas ES; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Pivot XB; Klimovsky JV; de Mendoza FH; Xu B; Campone M; Lerzo GL; Peck RA; Mukhopadhyay P; Vahdat LT; Roché HH
    J Clin Oncol; 2007 Nov; 25(33):5210-7. PubMed ID: 17968020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences.
    Hellerstedt-Börjesson S; Nordin K; Fjällskog ML; Rissanen R; Peterson M; Arving C
    Scand J Pain; 2018 Oct; 18(4):581-591. PubMed ID: 29949517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decline in the use of anthracyclines for breast cancer.
    Giordano SH; Lin YL; Kuo YF; Hortobagyi GN; Goodwin JS
    J Clin Oncol; 2012 Jun; 30(18):2232-9. PubMed ID: 22614988
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
    Chan S; Romieu G; Huober J; Delozier T; Tubiana-Hulin M; Schneeweiss A; Lluch A; Llombart A; du Bois A; Kreienberg R; Mayordomo JI; Antón A; Harrison M; Jones A; Carrasco E; Vaury AT; Frimodt-Moller B; Fumoleau P
    J Clin Oncol; 2009 Apr; 27(11):1753-60. PubMed ID: 19273714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer.
    Burdette-Radoux S; Muss HB
    Clin Breast Cancer; 2003 Oct; 4(4):264-72. PubMed ID: 14651771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
    Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
    J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
    Heinemann V
    Oncology; 2003; 64(3):191-206. PubMed ID: 12697958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
    Schwentner L; Harbeck N; Singer S; Eichler M; Rack B; Forstbauer H; Wischnik A; Scholz C; Huober J; Friedl TW; Weissenbacher T; Härtl K; Kiechle M; Janni W; Fink V
    Breast; 2016 Jun; 27():69-77. PubMed ID: 27054751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
    Murialdo R; Bertolotti F; Pastorino G; Mencoboni M; Bergaglio M; Folco U; Cinzia N; Vaira F; Simoni C; Canobbio L; Parodi M; Brema F; Ballestrero A
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1009-16. PubMed ID: 21327683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.